Arch Venture Partners
-
Health/Life Sciences
Juno’s lasting legacy: How the cell remedy juggernaut influenced biotech in Seattle and past
Juno’s scientific co-founders, from left: Michel Sadelain, Michael Jensen, Isabelle Rivière, Philip Greenberg, Stanley Riddell, and Renier Brentjens. (Juno Therapeutics…
Read More » -
Health/Life Sciences
ARCH Enterprise Companions raises near $3B for early-stage biotech fund
ARCH Enterprise Companions has closed a $2.975 billion fund focused for early-stage biotech corporations. The agency’s twelfth enterprise fund comes…
Read More »